Please try another search
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Leonard Kruimer | 63 | 2018 | Independent Chairman of the Board |
Kristoffer Bissessar | 54 | 2020 | Independent Director |
Thomas O. Hecht | 71 | 2020 | Independent Director |
Vessela Alexieva | 65 | - | Employee Representative Director |
Rienk Offringa | - | 2017 | Member of Scientific Advisory Board |
Vincent Ossipow | 56 | 2021 | Independent Director |
Alexander Rudensky | - | 2017 | Member of Scientific Advisory Board |
Falk Nimmerjahn | - | 2017 | Member of Scientific Advisory Board |
Bernd Robert Seizinger | 68 | 2018 | Independent Director |
Mark Cragg | - | - | Member of Scientific Advisory Board |
Nanna Luneborg | 48 | 2022 | Independent Director |
Alexander Maximiliaan Marie Eggermont | - | 2021 | Member of Scientific Advisory Board |
Stephen Beers | - | - | Member of Scientific Advisory Board |
Martin Palsson | 45 | 2022 | Employee Representative Director |
Natalie Brittenham Berner | 34 | 2022 | Independent Director |
Laura Lassouw-Polman | - | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review